We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 301.00
Ask: 304.00
Change: 14.00 (4.83%)
Spread: 3.00 (0.997%)
Open: 310.00
High: 314.00
Low: 304.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
21st Apr 20229:30 amRNSVesting of awards under Long Term Incentive Plan
31st Mar 20227:00 amRNSUpdate on Status under HFCAA
23rd Mar 20228:30 amRNS2021 Annual Report and Notice of AGM
11th Mar 20229:00 amRNSUpdate on Status under HFCAA
9th Mar 20228:30 amRNSVesting of awards under Long Term Incentive Plan
7th Mar 20227:00 amRNSHUTCHMED Receives $15m Milestone from AstraZeneca
3rd Mar 20223:30 pmRNSPublication of Form 20-F
3rd Mar 202212:30 pmRNSRetirement of CEO and appointment of new CEO
3rd Mar 202212:00 pmRNSFull Year Results and Business Updates
1st Mar 20228:30 amRNSApproval to Commercialize ELUNATE® in Macau
7th Feb 20228:30 amRNSHUTCHMED to Announce 2021 Final Results
4th Feb 20229:30 amRNSPhase Ib/II Combination Study of HMPL-453
20th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-653
19th Jan 20227:00 amRNSHUTCHMED Data at ASCO GI Cancers Symposium
17th Jan 20229:00 amRNSHolding(s) in Company
12th Jan 202211:00 amRNSBreakthrough Therapy Designation for HMPL-523
10th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Study of HMPL-760
31st Dec 20217:00 amRNSBlocklisting Six Monthly Return
31st Dec 20217:00 amRNSTotal Voting Rights
20th Dec 20217:00 amRNSHUTCHMED Included in FTSE Russell Indexes
15th Dec 20219:45 amRNSGrant of Share Options and Awards under LTIP
14th Dec 20217:00 amRNSHMPL-523 Clinical Data Presented at ASH
10th Dec 202110:00 amRNSHUTCHMED Presents Data at ESMO Immuno-Oncology ‘21
6th Dec 20217:00 amRNSHUTCHMED Completes Planned Enrollment of FRESCO-2
3rd Dec 20217:00 amRNSUpdated NRDL to include ELUNATE and SULANDA
30th Nov 20218:30 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSHUTCHMED and AZ Initiate SACHI Phase 3 Trial
8th Nov 20217:00 amRNSHUTCHMED to Present Clinical Data at ASH
1st Nov 20217:00 amRNSHUTCHMED and AZ Initiate SAMETA Global P3 Trial
29th Oct 20219:30 amRNSTotal Voting Rights
28th Oct 20217:00 amRNSHUTCHMED Initiates Phase III Trial of HMPL-523
20th Oct 20219:30 amRNSGrant of Awards under Long Term Incentive Plan
30th Sep 20219:30 amRNSTotal Voting Rights
29th Sep 20217:00 amRNSClosure of Non-Core OTC Joint Venture Divestment
29th Sep 20217:00 amRNSHUTCHMED Highlights Presentations at CSCO 2021
21st Sep 20217:00 amRNSHUTCHMED Initiates Phase III Trial SURTORI-01
20th Sep 20217:00 amRNSJapan Bridging Study For Surufatinib Initiated
13th Sep 20217:00 amRNSBreakthrough Therapy Designation for Amdizalisib
8th Sep 202111:30 amRNSHUTCHMED and AZ Initiate Phase III Trial in China
7th Sep 20219:30 amRNSHUTCHMED to Present Clinical Data at ESMO
2nd Sep 202112:45 pmRNSGrant of Share Options, and Awards under LTIP
31st Aug 20219:30 amRNSTotal Voting Rights
26th Aug 20217:00 amRNSPhase Ib/II Trial of Fruquintinib & Tislelizumab
23rd Aug 20217:00 amRNSHUTCHMED Selected for Certain Hang Seng Indexes
17th Aug 20219:30 amRNSELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
9th Aug 20217:00 amRNSHUTCHMED & Epizyme Announce TAZVERIK Collaboration
30th Jul 20219:30 amRNSTotal Voting Rights
28th Jul 202112:00 pmRNSInterim Results and Business Updates
28th Jul 20217:00 amRNSPhase II Trial of ORPATHYS Initiated
23rd Jul 202112:01 pmRNSStabilizing Actions & End of Stabilization Period

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.